<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6155">
  <stage>Registered</stage>
  <submitdate>10/08/2016</submitdate>
  <approvaldate>10/08/2016</approvaldate>
  <nctid>NCT02870634</nctid>
  <trial_identification>
    <studytitle>Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND</studytitle>
    <scientifictitle>A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CMD-2016-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Amyotrophic Lateral Sclerosis</healthcondition>
    <healthcondition>Motor Neuron Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cu(II)ATSM

Experimental: Cu(II)ATSM - Cu(II)ATSM capsules, administered orally once daily


Treatment: drugs: Cu(II)ATSM
copper-containing synthetic small molecule

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>recommended phase 2 dose as determined by the number of participants at each dose level with dose limiting toxicities</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in disease severity by ALS Functional Rating Scale - Revised (ALSFRS-R)</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in cognitive function by Edinburgh Cognitive and Behavioral Assessment (ECAS) score</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in respiratory function by seated forced vital capacity (FCV)</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in quality of life by ALSSQOL-R score</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in disease severity by transcranial magnetic stimulation (TMS) response</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peak Cu(II)ATSM plasma concentration following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the Cu(II)ATSM plasma concentration versus time curve (AUC) following administration of a single dose based on blood draws taken at 1, 2, 4, 8 and 24 hours after dosing</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment-related change in respiratory function by sniff nasal pressure (SNP) test</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Signed informed consent prior to initiation of any study-specific procedures;

          -  Familial or sporadic ALS/MND defined as clinically possible, probable, or definite by
             Awaji-shima Consensus Recommendations;

          -  First ALS/MND symptoms occurred no more than 2 years prior to screening visit;

          -  Seated FVC = 70% and SNP = 50% of predicted value;

          -  Not taking riluzole or on a stable dose of riluzole for at least 4 weeks prior to
             screening visit (participants are not allowed to start taking riluzole during the
             study);

          -  Age between 18 and 75 years at time of informed consent;

          -  Patient has a competent caregiver who can and will be responsible for administration
             of study drug;

          -  Adequate bone marrow reserve, renal and liver function:

               -  absolute neutrophil count = 1500/µL

               -  lymphocyte count &lt; 48%

               -  platelet count = 150,000/µL

               -  hemoglobin = 11 g/dL

               -  creatinine clearance = 60 mL/min (Cockroft &amp; Gault formula)

               -  ALT and/or AST = 2 x ULN

               -  total bilirubin = 1.5 x ULN

               -  serum albumin = 2.8 g/dL

          -  Women and men with partners of childbearing potential must take effective
             contraception while on study and women of childbearing potential must have a negative
             pregnancy test and be non-lactating at screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Inability to swallow oral medications or presence of GI disorder deemed to jeopardize
             intestinal absorption of Cu(II)ATSM

          -  Dependence of mechanical ventilation (non-invasive or invasive) for any part of day or
             night

          -  Exposure to any other investigational agent within 3 months or two investigational
             agents within 6 months prior to screening visit

          -  Active GI disease (except gastrointestingal reflux disease) within 30 days of
             screening visit

          -  Known immune compromising illness or treatment

          -  Presence of any of the following clinical conditions

               -  drug abuse or alcoholism

               -  unstable cardiac, pulmonary, renal, hepatic, endocrine or hematologic disorder

               -  active infectious disease

               -  AIDS or AIDS-related complex

               -  current malignancy

               -  unstable psychiatric illness, defined as psychosis or untreated major depression
                  within 90 days of screening visit

               -  neuromuscular disease other than ALS/MND

          -  Dementia that may affect either outcome measures or patient understanding and/or
             compliance with study requirements and procedures

          -  Use of anticoagulants at therapeutic doses within 7 days prior to screening visit

          -  Current use of strong inducers or inhibitors of CYPs 2C19 and 2D6</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Macquarie University - Sydenham</hospital>
    <hospital>Calvary Health Care Bethlehem - Caulfield</hospital>
    <postcode>2109 - Sydenham</postcode>
    <postcode>3162 - Caulfield</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Collaborative Medicinal Development Pty Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02870634</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dominic Rowe, MD</name>
      <address>Macquarie University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Kay Noel, PhD</name>
      <address />
      <phone>415 444 9602</phone>
      <fax />
      <email>kay.noel@ColMedDev.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>